Provided by Tiger Trade Technology Pte. Ltd.

Spero Therapeutics Inc.

1.23
+0.01501.23%
Post-market: 1.250.0165+1.34%16:28 EDT
Volume:645.51K
Turnover:794.76K
Market Cap:71.63M
PE:9.63
High:1.26
Open:1.23
Low:1.20
Close:1.22
52wk High:3.08
52wk Low:1.08
Shares:58.23M
Float Shares:45.59M
Volume Ratio:1.44
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1278
EPS(LYR):0.1500
ROE:19.17%
ROA:7.19%
PB:1.62
PE(LYR):8.20

Loading ...

Spero Q2 FY26 Net Loss Widens to $9.6 Million; Revenue Posts no Revenue

Reuters
·
Aug 13

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

THOMSON REUTERS
·
Aug 13

Spero Therapeutics, - no Revenue Recognized in Q2 2026

THOMSON REUTERS
·
Aug 13

Spero Therapeutics CMO Debra Zack Files Initial Beneficial Ownership Statement

Reuters
·
Aug 07

Spero Therapeutics Grants New Hire 324,622 Stock Options, 162,311 RSUs Under Inducement Plan

Reuters
·
Aug 06

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

THOMSON REUTERS
·
Aug 05

Spero Therapeutics Appoints Debra Jeske Zack, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
Jul 27

Press Release: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Dow Jones
·
Jul 27

Innovent Biologics Shares Surge on Spero Deal That Could be Worth $1.1 Bln

Dow Jones
·
Jul 15

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Jul 14

Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics secures $105M non-dilutive financing to develop SP001

TIPRANKS
·
Jul 14

Spero Therapeutics Secures $105 Million Royalty-backed Financing from Healthcare Royalty (KKR)

Reuters
·
Jul 14

Spero Therapeutics - Updates Cash Runway Guidance into Second Half of 2029

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Hcrx to Provide $105 Mln Payment at Closing for Rights to Utebzi Payments from GSK

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Proceeds to Support Advancement of Lead Immunology Drug Candidate SP001

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Retain 35% of Subsequent GSK Payments Related to Utebzi Sales After Repayment

THOMSON REUTERS
·
Jul 14

Spero Therapeutics Announces $105 Million Non-recourse Non-dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Hcrx to Receive Quarterly Principal and Interest Payments Derived from the GSK Payments Due to Spero Until Loan Repaid

THOMSON REUTERS
·
Jul 14

Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion

Reuters
·
Jul 14